These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 11870528)

  • 1. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.
    Bokemeyer C; Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Claussen CD; Bares R; Kanz L
    Br J Cancer; 2002 Feb; 86(4):506-11. PubMed ID: 11870528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
    Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
    Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment.
    Raggi D; Bandini M; Giannatempo P; Farè E; Marandino L; Colecchia M; Calareso G; Padovano B; Serafini G; Alessi A; Necchi A
    Clin Genitourin Cancer; 2021 Jun; 19(3):237-245.e2. PubMed ID: 32980271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
    Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
    Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Loriot Y; Texier M; Culine S; Fléchon A; Thiery-Vuillemin A; Gravis G; Geoffrois L; Chevreau C; Gross-Goupil M; Barthelemy P; Bompas E; Mahammedi H; Laguerre B; Lacourtoisie SA; Helissey C; Ladoire S; Abraham C; Massard C; Grimaldi S; Fizazi K
    Eur Urol; 2022 Aug; 82(2):172-179. PubMed ID: 35599187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
    Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
    Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up.
    Karapetis CS; Strickland AH; Yip D; Steer C; Harper PG
    Intern Med J; 2003; 33(9-10):427-35. PubMed ID: 14511195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].
    Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R
    Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
    De Santis M; Bokemeyer C; Becherer A; Stoiber F; Oechsle K; Kletter K; Dohmen BM; Dittrich C; Pont J
    J Clin Oncol; 2001 Sep; 19(17):3740-4. PubMed ID: 11533096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Assessment of residual tumours after systemic treatment of metastatic seminoma: ¹⁸F-2-fluoro-2-deoxy-D-glucose positron emission tomography - meta-analysis of diagnostic value].
    Müller J; Schrader AJ; Jentzmik F; Schrader M
    Urologe A; 2011 Mar; 50(3):322-7. PubMed ID: 21161157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of 18F-FDG PET/CT in the management of testicular cancers.
    Cook GJ; Sohaib A; Huddart RA; Dearnaley DP; Horwich A; Chua S
    Nucl Med Commun; 2015 Jul; 36(7):702-8. PubMed ID: 25757201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim (18)F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions.
    Necchi A; Nicolai N; Alessi A; Miceli R; Giannatempo P; Raggi D; Tana S; Serafini G; Padovano B; Mariani L; Crippa F; Salvioni R
    Clin Genitourin Cancer; 2016 Jun; 14(3):249-54. PubMed ID: 26433626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
    Decoene J; Winter C; Albers P
    Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group.
    Huddart RA; O'Doherty MJ; Padhani A; Rustin GJ; Mead GM; Joffe JK; Vasey P; Harland SJ; Logue J; Daugaard G; Hain SF; Kirk SJ; MacKewn JE; Stenning SP;
    J Clin Oncol; 2007 Jul; 25(21):3090-5. PubMed ID: 17634488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K; Hay JH; Wilson DC
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
    Spermon JR; De Geus-Oei LF; Kiemeney LA; Witjes JA; Oyen WJ
    BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
    Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor markers and
    Dondi F; Albano D; Bertagna F; Giubbini R
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(5):287-292. PubMed ID: 34425969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
    Becherer A; De Santis M; Karanikas G; Szabó M; Bokemeyer C; Dohmen BM; Pont J; Dudczak R; Dittrich C; Kletter K
    Eur J Radiol; 2005 May; 54(2):284-8. PubMed ID: 15837411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.